Is IMCC or KNSA more undervalued in 2026?

CirclFi compares IM Cannabis Corp. (IMCC) and Kiniksa Pharmaceuticals Interna (KNSA) using 13 institutional-grade valuation models. IMCC has a Quality of Company score of 5.4/10 while KNSA scores 5.5/10.

Which is a better buy — IMCC or KNSA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do IMCC and KNSA valuations compare?

IMCC at $0.29 and KNSA at $50.84 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

IMCC vs KNSA Valuation Comparison 2026 — Intrinsic Value Analysis

IMCC

Drug Manufacturers - Specialty & Generic

IM Cannabis Corp.

Quality

5.4

out of 10

Value Trap

SAFE

Price

$0.29

Last close

Models

4/13

Active

KNSA

Drug Manufacturers - Specialty & Generic

Kiniksa Pharmaceuticals Interna

Quality

5.5

out of 10

Value Trap

SAFE

Price

$50.84

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	IMCC Fair Value	IMCC Upside	KNSA Fair Value	KNSA Upside
Bayesian DCF	Intrinsic	—	—	$6.16	-87.9%
Earnings Power Value	Intrinsic	$1.11	+282.0%	$9.70	-80.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.29	-2.1%	$17.29	-66.0%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for IMCC vs KNSA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IMCC vs KNSA — Which Stock Is More Undervalued?

KNSA scores higher with a 5.5/10 quality rating vs IMCC's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing IM Cannabis Corp. (IMCC) and Kiniksa Pharmaceuticals Interna (KNSA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IMCC currently trades at $0.29 with a QOC of 5.4/10, while KNSA trades at $50.84 with a QOC of 5.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).